

ALLOCATION ROUND 4: AstraZeneca/Oxford Vaccine

Exceptional allocation to address 2nd dose needs and shipment delays

16 July 2021

Introduction

Based on current knowledge of COVID-19 vaccine supply availability, this fourth round of COVAX Facility allocations provides information on the provision of 17,366,400 doses of the AstraZeneca/Oxford vaccine to 43 COVAX Facility participants, to be supplied as soon as possible.

Allocation in this round is focused on Facility participants that have experienced delays in shipments in doses allocated by the Facility via [Round 2](#), due to disruptions in supply of the AstraZeneca/Oxford vaccine licensed and manufactured by the Serum Institute of India (SII/AZ). Specifically, this fourth allocation round covers 38 Facility participants that received first shipments of SII/AZ and are now awaiting supply to administer second doses, as well as 5 Facility participants that did not receive first shipments due to preparedness or supply reasons.

Further allocation rounds will be announced shortly.

Overview of the process

This fourth round of allocation was run primarily to cover the second dose needs of COVAX participants previously allocated SII who used the majority or entirety of their first shipment as first doses, as well as a small number of participants that did not receive first shipments.

Due to a surge in COVID-19 infections in the country, the Government of India halted the export of vaccines produced by the Serum Institute of India, therefore interrupting the supply of SII doses to the COVAX Facility beginning in March 2021. In Round 2, around 161.5 million SII doses had been allocated to 60 AMC participants for the period January to May 2021. In the period preceding the halt in the export of vaccines produced by the Serum Institute of India, only a small proportion of allocated SII doses had been delivered as first tranche shipments to participants, many of whom reported having used them primarily as first doses to target high risk populations.

COVAX

As the Allocation Framework aims to allocate full courses, in this case constituting a two-dose regimen, this development necessitated the running of this exceptional allocation round to address second dose needs. This is made possible in light of [WHO guidance on the interchangeability of all AstraZeneca vaccines](#), including AZ and SII.

The operationalization of the COVAX Allocation Framework, in accordance with the principles and provisions set forth in the document, is performed by the Joint Allocation Taskforce (JAT), composed of staff from Gavi, the Vaccine Alliance and WHO, and the [Independent Allocation of Vaccines Group \(IAVG\)](#).

To undertake this allocation, the JAT manually allocated the exact quantity of doses to match the volume of SII doses delivered from February through April 2021 – meaning, exceptionally, the algorithm was not used. The [JAT proposal](#) was then validated by the COVAX Allocation Leadership Group on 8 June 2021. Considering the exceptional circumstances for Round 4, the proposal did not require approval from the IAVG.

TABLE: Round 4 allocations, by Facility Participant*

** **Disclaimer:** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of COVAX partners concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.*

#	Participant	WHO region	Participation model	Doses allocated: Round 4 AZ
1	Afghanistan	EMR	AMC92	468000
2	Angola	AFR	AMC92	129600
3	Bangladesh	SEAR	AMC92	1000800
4	Benin	AFR	AMC92	93600
5	Bhutan	SEAR	AMC92	108000
6	Bolivia	AMR	AMC92	228000
7	Cambodia	WPR	AMC92	324000
8	Cameroon	AFR	AMC92	391200
9	Comoros	AFR	AMC92	12000
10	Côte d'Ivoire	AFR	AMC92	355200
11	Djibouti	EMR	AMC92	24000
12	Ethiopia	AFR	AMC92	1792800
13	Gambia	AFR	AMC92	36000

COVAX

#	Participant	WHO region	Participation model	Doses allocated: Round 4 AZ
14	Ghana	AFR	AMC92	249600
15	Guinea	AFR	AMC92	194400
16	Guinea-Bissau	AFR	AMC92	28800
17	Haiti	AMR	AMC92	129600
18	Kenya	AFR	AMC92	765600
19	Kyrgyzstan	EUR	AMC92	228000
20	Lao People's Democratic Republic	WPR	AMC92	132000
21	Liberia	AFR	AMC92	96000
22	Malawi	AFR	AMC92	360000
23	Maldives	SEAR	AMC92	12000
24	Mali	AFR	AMC92	396000
25	Mozambique	AFR	AMC92	276000
26	Nepal	SEAR	AMC92	348000
27	Nicaragua	AMR	AMC92	134400
28	Niger	AFR	AMC92	254400
29	Nigeria	AFR	AMC92	3924000
30	Pakistan	EMR	AMC92	1000800
31	Senegal	AFR	AMC92	139200
32	Sierra Leone	AFR	AMC92	96000
33	Somalia	EMR	AMC92	192000
34	South Sudan	AFR	AMC92	60000
35	Sri Lanka	SEAR	AMC92	264000
36	Sudan	EMR	AMC92	828000
37	Syrian Arab Republic ¹	EMR	AMC92	256800

¹ A portion of these doses are allocated for distribution through international partners under the humanitarian response, given unique country context

COVAX

#	Participant	WHO region	Participation model	Doses allocated: Round 4 AZ
38	Tajikistan	EUR	AMC92	192000
39	Togo	AFR	AMC92	16800
40	Uganda	AFR	AMC92	688800
41	Uzbekistan	EUR	AMC92	660000
42	Yemen	EMR	AMC92	360000
43	Zambia	AFR	AMC92	120000